Relevant bibliographies by topics / Grade de Gleason

Contents

  1. Journal articles
  2. Dissertations / Theses
  3. Books
  4. Book chapters
  5. Conference papers
  6. Reports

Academic literature on the topic 'Grade de Gleason'

Author: Grafiati
Published: 4 June 2021
Last updated: 7 February 2022

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Grade de Gleason.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "Grade de Gleason"

1

Gupta, Sajjan, Ishan Dubey, Vandana Agarwal, and Shalakha Agarwal. "New perspectives in modified Gleason’s grading for prostatic cancer and its comparison with original Gleason’s." International Journal of Research in Medical Sciences 7, no. 2 (January 25, 2019): 400. http://dx.doi.org/10.18203/2320-6012.ijrms20190342.

Full text
Abstract:
Background: The Gleason score is the most widely accepted histopathological grading system for prostate cancer since decade despite having many deficiency that can potentially impact patient health care. So ISUP agreed on developing a system of prognostic grade groups from I-V. Aim and objective was to study the new perspectives of modified Gleason’s grading and to compare it with original Gleason’s System with focus on the prognostic significance of the modifications.Methods: A retrospective study of 60 patients, who underwent TURP and Sextant biopsy and diagnosed as prostatic carcinoma in our institute were included in this study. Laboratory requisition forms with clinical history, PSA levels and histopathology reports of these patients were reviewed and graded accordingly to the newer gleasons. New Gleason grade includes five distinct Grade Groups based on the modified Gleason score groups. Grade Group 1 = Gleason score ≤6, Grade Group 2 = Gleason score 3 + 4 = 7, Grade Group 3 = Gleason score 4 + 3 = 7, Grade Group 4 = Gleason score 8, Grade Group 5 = Gleason scores 9 and 10 were assigned. The change in the grading system is tabulated and compared separately.Results: Patients age ranged from 55-80 years. The number of cases were 3,12,15,19 and 11 categorized under grade group I, grade group II, grade group III, grade group IV, grade group V cancer respectively according to modified gleason grading.Conclusions: Modified Gleason is a simplified grading system which may reduce over treatment of indolent prostate cancer. New gleasons grading clarifies the clinicians about the dilemma of gleason scores, offering an excellent prognostic stratification of this carcinoma.
APA, Harvard, Vancouver, ISO, and other styles
2

Tilki, D., F. Preisser, H. Huland, M. Graefen, F. Chun, and P. Mandel. "Gleason grade grouping: The significance of primary Gleason 5 in patients with Gleason grade group 5." European Urology Supplements 18, no. 1 (March 2019): e2186. http://dx.doi.org/10.1016/s1569-9056(19)31579-9.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Penney, Kathryn L., Meir J. Stampfer, Jaquelyn L. Jahn, Jennifer A. Sinnott, Richard Flavin, Jennifer R. Rider, Stephen Finn, et al. "Gleason Grade Progression Is Uncommon." Cancer Research 73, no. 16 (August 13, 2013): 5163–68. http://dx.doi.org/10.1158/0008-5472.can-13-0427.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Trock, Bruce J., Robert B. Jenkins, Jonathan W. Said, Samson Fine, Beatrice Knudsen, Helen L. Fedor, Bora Gurel, Tamara L. Lotan, and Angelo M. De Marzo. "Chromosome 8 alterations and PTEN loss in Gleason grade 3 tumor to predict the presence of unsampled grade 4 tumor: Implications for active surveillance." Journal of Clinical Oncology 32, no. 4_suppl (February 1, 2014): 93. http://dx.doi.org/10.1200/jco.2014.32.4_suppl.93.

Full text
Abstract:
93 Background: A key eligibility criterion in many active surveillance (AS) programs is that the biopsy exhibit only Gleason pattern 3 (G3) for a Gleason score of 6 or less. However, 25 to 35% of biopsy Gleason 6 is upgraded to Gleason 7 or higher in the prostatectomy (RP) specimen. Thus, there is a great need for biomarkers that, when measured on G3 tissue in a Gleason 6 biopsy, can predict the presence of unsampled higher grade tumor in the whole prostate. We evaluated PTEN loss by immunohistochemistry (IHC), and PTEN deletion, chromosome 8q (MYC) gain and 8p (LPL) loss by fluorescence in situ hybridization (FISH) for their ability to predict unsampled G4 tumor. Methods: A tissue microarray (TMA) was constructed of RP tissue from three groups of patients (n=50 per group) whose prostates exhibited only Gleason 3+3, only 3+4, or only 4+3 tumor, matched on age, year of RP, and race. In each patient, multiple cores sampled only from areas of G3 were evaluated for PTEN deletion by FISH, PTEN loss by IHC, and chromosome 8p/8q alterations by FISH. Biomarker results were compared between Gleason 6 versus 7 tumors using conditional logistic regression. Results: Patients underwent RP in 2001 to 2009, had median age 60, and median prostate-specific antigen 5.2; 63% of tumors were organ confined. In univariate analyses 8q gain (odds ratio OR=8.9, p<.0001), 8p loss (OR=6.9, p<.0001), PTEN loss by IHC (OR=5.7, p=.025), but not PTEN deletion by FISH (OR=1.5, p=.477) were significantly more common in G3 cores from Gleason 7 tumors than G3 cores from Gleason 6 tumors. In multivariable analyses, 8q gain (OR=6.2, p=.002) and 8p loss (OR=5.2, p=.0002) remained highly significant. At least one high risk biomarker (8q gain, 8p loss, PTEN loss, or PTEN deletion) was found in 35.7% of Gleason 3+3 versus 77.1% of Gleason 3+4 versus 91.3% of Gleason 4+3 tumors, p<.0001. Adjustment for confounding factors did not change the results. Conclusions: Chromosomal 8q gains (MYC), 8p loss (LPL), and PTEN loss measured in Gleason G3 TMA cores strongly differentiate whether the core comes from Gleason 6 or Gleason 7 tumor. If validated in biopsy Gleason 6 cores to predict prostatectomy Gleason 7 tumor these biomarkers could facilitate safe selection of men for active surveillance.
APA, Harvard, Vancouver, ISO, and other styles
5

Kristiana, Tjandra, I. Gusti Ayu Sri Mahendra Dewi, Luh Putu Iin Indrayani Maker, Herman Saputra, Ni Putu Sriwidyani, and I. Made Muliarta. "Loss of Phosphatase and Tensin Homologue (PTEN) Expression Associated with Higher Risk Grade Group Gleason Prostate Adenocarcinoma in Sanglah Hospital Denpasar." Indonesian Journal of Cancer 13, no. 4 (December 27, 2019): 127. http://dx.doi.org/10.33371/ijoc.v13i4.680.

Full text
Abstract:
Background: Prostate cancer is the second most common malignancy in men and the fifth most common cause of death worldwide. In Asia, 59.3% of patients come for the advanced stage treatment. PTEN inactivation is identified in about 20% of primary prostate tumors in radical prostatectomy and the loss of PTEN is associated with poor clinical and pathological outcomes. The purpose of this study is to prove that there is an association between PTEN expression and risk grade group Gleason prostate adenocarcinoma in Sanglah Public Hospital, Denpasar.Methods: This is a cross-sectional study. The sample size of this study was 35 paraffin blocks. These samples were selected by proportional stratified random sampling from hematoxylin-eosin preparation. Prostate adenocarcinoma was regrouped into 3 categories based on NCCN risk stratification: low risk grade group Gleason (Gleason score ≤ 6), intermediate risk grade group Gleason (Gleason score 7), and high-risk grade group Gleason (Gleason score 8–10). Immunohistochemistry examination of PTEN was performed and the expression was evaluated by scoring method. The data were analyzed by Chi-square and logistic regression.Results: The analysis result showed that there is an association between PTEN expression and risk grade group Gleason that is statistically significant. The loss of PTEN expression associated with higher risk grade group Gleason is of the higher proportion with p=0.001; PR 3.339; 95% CI: 1.296–8.599, but there is no association between the proportion loss of PTEN expression heterogeneously or homogeneously and the risk grade group Gleason with p=0.742; PR 0.663; 95% CI: 0.179–2.457.Conclusions: This study has proved that PTEN expression is associated with higher risk grade group Gleason prostate adenocarcinoma.
APA, Harvard, Vancouver, ISO, and other styles
6

Feuerstein, Michael, Tipu Nazeer, and Badar M. Mian. "CORRELATION BETWEEN GLEASON GRADE AT THE SURGICAL MARGIN WITH THE PRIMARY GLEASON GRADE AND BIOCHEMICAL FAILURE." Journal of Urology 179, no. 4S (April 2008): 653. http://dx.doi.org/10.1016/s0022-5347(08)61909-6.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Penney, Kathryn L., Jennifer A. Sinnott, Katja Fall, Yudi Pawitan, Yujin Hoshida, Peter Kraft, Jennifer R. Stark, et al. "mRNA Expression Signature of Gleason Grade Predicts Lethal Prostate Cancer." Journal of Clinical Oncology 29, no. 17 (June 10, 2011): 2391–96. http://dx.doi.org/10.1200/jco.2010.32.6421.

Full text
Abstract:
Purpose Prostate-specific antigen screening has led to enormous overtreatment of prostate cancer because of the inability to distinguish potentially lethal disease at diagnosis. We reasoned that by identifying an mRNA signature of Gleason grade, the best predictor of prognosis, we could improve prediction of lethal disease among men with moderate Gleason 7 tumors, the most common grade, and the most indeterminate in terms of prognosis. Patients and Methods Using the complementary DNA–mediated annealing, selection, extension, and ligation assay, we measured the mRNA expression of 6,100 genes in prostate tumor tissue in the Swedish Watchful Waiting cohort (n = 358) and Physicians' Health Study (PHS; n = 109). We developed an mRNA signature of Gleason grade comparing individuals with Gleason ≤ 6 to those with Gleason ≥ 8 tumors and applied the model among patients with Gleason 7 to discriminate lethal cases. Results We built a 157-gene signature using the Swedish data that predicted Gleason with low misclassification (area under the curve [AUC] = 0.91); when this signature was tested in the PHS, the discriminatory ability remained high (AUC = 0.94). In men with Gleason 7 tumors, who were excluded from the model building, the signature significantly improved the prediction of lethal disease beyond knowing whether the Gleason score was 4 + 3 or 3 + 4 (P = .006). Conclusion Our expression signature and the genes identified may improve our understanding of the de-differentiation process of prostate tumors. Additionally, the signature may have clinical applications among men with Gleason 7, by further estimating their risk of lethal prostate cancer and thereby guiding therapy decisions to improve outcomes and reduce overtreatment.
APA, Harvard, Vancouver, ISO, and other styles
8

Pudasaini, Sujata, and Neeraj Subedi. "Understanding the gleason grading system and its changes." Journal of Pathology of Nepal 9, no. 2 (September 29, 2019): 1580–85. http://dx.doi.org/10.3126/jpn.v9i2.25723.

Full text
Abstract:
Gleason Grading System is the most widely used grading system used for prostatic carcinoma. The five basic grade patterns are used to generate a histologic score, which can range from 2 to 10 (including primary and secondary patterns). The original Gleason Grading System was used to grade acinar adenocarcinoma based on architectural features and it has been correlated with excellent clinical outcomes. Since 1960s, after the discovery of the original Gleason Grading System, a modified version of the Gleason Grading System was introduced in the International Society of Urological Pathology 2005 which came up with many changes including elimination of Gleason pattern 1. The ISUP 2005 was further updated in 2014 to provide more accurate stratification of prostatic carcinoma. The new Gleason Grade Group 1 to 5 has been introduced and it has little resemblance to the original Gleason system. This Gleason Grade Group has been accepted by the 2016 World Health Organization classification of tumors of the prostate. For a needle biopsy, high grade component of any quantity should be included in the Gleason score as it indicates a high probability of finding significant high grade tumor in the prostate. By understanding the principles and practice of this grading system, the pathology report has to clearly indicate which system is adopted in the reporting. This review discusses GGS and its recent development focusing on major changes over the years that led to the new Grade Group system proposed by the 2014 ISUP consensus.
APA, Harvard, Vancouver, ISO, and other styles
9

VanderWeele, David James, Christopher D. Brown, Robert L. Grossman, Jerome B. Taxy, Walter Michael Stadler, and Kevin P. White. "The genomic relationship among matched prostate cancer foci." Journal of Clinical Oncology 31, no. 15_suppl (May 20, 2013): 5028. http://dx.doi.org/10.1200/jco.2013.31.15_suppl.5028.

Full text
Abstract:
5028 Background: Cancer management is influenced by how one views progression and how one calculates the risk of metastases and death. For prostate cancer, this is based largely on histologic appearance, or Gleason score. Cancers with a Gleason score of 6 exhibit indolent behavior and are often considered low risk. Despite recommendations supporting active surveillance for Gleason 6 prostate cancer, the vast majority of American patients receive aggressive local therapy, in part based on a presumption that low grade cancer progresses to high grade, lethal disease. Methods: To assess the genomic relationship between low and high grade disease, laser capture microdissection was used to isolate concurrent cancer foci from prostates with multifocal disease, and somatic mutations were identified using exome sequencing. The relationship between a Gleason 6 focus and a concurrent Gleason 8 or higher focus was determined for four subjects, and a lymph node metastasis was examined for two of those subjects. Results: We obtained an average of 41-fold median coverage of the exome, with an average high confidence mutation rate of 0.8/Mb. Seventy of 79 (0.886) high confidence somatic mutations in low grade disease were private to the low grade foci. For the cases for which a metastatic focus was available, 15 of 80 (0.188) high confidence somatic mutations in the high grade focus were private. Seven of the 80 (0.088) were shared with low grade foci, and 65 (0.813) were shared with metastatic foci. Conclusions: The pattern of shared versus private mutations is consistent with early divergence between Gleason 6 and Gleason 8 or 9 disease, and late divergence between Gleason 8 disease and lymph node metastases. These data support a model of parallel evolution of lower and higher Gleason score disease, rather than progression from Gleason 6 to higher Gleason scores.
APA, Harvard, Vancouver, ISO, and other styles
10

Larasati, Putri Ajeng ayu. "KORELASI ANTARA EKSPRESI Her-2 DAN Ki-67 DENGAN GLEASON GRADE GROUP PADA ADENOKARSINOMA ASINAR PROSTAT." Jurnal Kedokteran RAFLESIA 5, no. 1 (October 31, 2019): 39–52. http://dx.doi.org/10.33369/juke.v5i1.9125.

Full text
Abstract:
Latar Belakang : Menurut Database GLOBOCAN 2012, kanker prostat merupakan penyebab utama kelima kematian pada pria.(1) Pemahaman tentang peran onkogen dan tumor suppressor genes mendominasi penelitian tentang biologi kanker saat ini dan berpotensi menghasilkan target terapi kanker terbaru. Salah satu perannya pada adenokarsinoma prostat yang masih belum jelas ialah Her-2 dan Ki-67. Perbedaan ekspresi profil molekular Her-2 dan Ki-67 yang diklasifikasikan berdasarkan Gleason grading system terbaru yaitu Grade group diharapkan membantu penentuan prognosis dan manajemen terapi penyakit pada kanker prostat.Tujuan : Tujuan dari penelitian ini adalah untuk mengetahui korelasi antara ekspresi Her-2 dan Ki-67 dengan Gleason Grade group adenokarsinoma asinar prostat.Metode: Merupakan penelitian observatif analitik dengan desain cross-sectional menggunakan 31 blok parafin yang terfiksasi formalin dari laboratorium Patologi Anatomik RSUP dr. Kariadi, dengan diagnosis adenokarsinoma asinar prostat kemudian diklasifikasikan menurut kelompok prognostik WHO / ISUP Gleason (Gleason Grade group 1 - 5). Pemeriksaan imunohistokimia dilakukan dengan menggunakan antibodi Her-2 dan Ki-67. Analisa hasil menggunakan uji Spearmans dan uji Kruskal WallisHasil : 31 kasus yang termasuk dalam kriteria inklusi pada penelitian ini, hampir separuhnya (41.94%) termasuk ke dalam Gleason grade group 5. Ekspresi Her-2 positif (+1, +2, +3) hampir didapatkan pada seluruh sampel (90,22%), dengan Her-2 +3 sebagian besar didapatkan pada grade group 5 (71,43%). Ekspresi Ki-67 positif (+1, +2, +3) didapatkan pada seluruh sampel, dengan Ki-67 +3 (>5%) pada Gleason grade group 5 didapatkan sejumlah 5 sampel (38,46%). Pada analisa data dengan uji Spearmans disimpulkan bahwa terdapat korelasi positif antara ekspresi Her-2 dan Ki-67 dengan Gleason Grade group. Pada uji Kruskal Wallis didapatkan perbedaan bermakna antara ekspresi Ki-67 dengan Gleason Grade group.Kesimpulan: Analisa ekspresi Her-2 dan Ki-67 melalui pemeriksaan imunohistokimia dengan klasifikasi terbaru Gleason Grade group dapat menjadi salah satu parameter prognosis dan manajemen terapi pada adenokarsinoma asinar prostat.Kata kunci : Adenokarsinoma asinar prostat, Her-2, Ki-67, Gleason Grade group
APA, Harvard, Vancouver, ISO, and other styles
More sources

Dissertations / Theses on the topic "Grade de Gleason"

1

Folkvaljon, Yasin. "Prognostic value of the ISUP 2015 Gleason grade groupings." Thesis, Uppsala universitet, Statistiska institutionen, 2015. http://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-256158.

Full text
Abstract:
Background: New prognostic grade groupings were recently proposed for prostate cancer. They are based on Gleason grading of either biopsy or prostatectomy specimen. Former Gleason 6 corresponds to group 1, Gleason 7=3+4 corresponds to group 2, Gleason 7=4+3 corresponds to group 3, Gleason 8 corresponds to group 4, and Gleason 9-10 correspond to group 5. Objective: To assess the prognostic value of Gleason grade groups in men with prostate cancer from a nationwide population‑based cohort. Design, Setting and Participants: From the National Prostate Cancer Register of Sweden, we identified 5,880 men diagnosed with prostate cancer from 2005 to 2007, including 4,325 who had radical prostatectomy and 1,555 treated by radiotherapy.  Outcome Measurements and Statistical Analysis: Kaplan-Meier survival analysis was used to calculate the cumulative 4-year biochemical recurrence-free survival. Cox proportional hazards regression models were used to examine the relationship between prognostic Gleason grade groups and biochemical recurrence after radical prostatectomy and radiotherapy. The 4-year biochemical progression-free survival was compared for groups based on biopsy and prostatectomy Gleason grade groups. Results and Limitations: Among men undergoing surgery, the 4‑year biochemical progression-free survival was 89%, 82%, 74%, 77%, and 49% for prognostic Gleason grade groups 1-5 on biopsy. The corresponding 4-year biochemical progression-free survival based on prostatectomy prognostic Gleason grade groups was 92%, 85%, 73%, 63%, and 51% for prognostic Gleason grade groups 1-5. For men undergoing radiotherapy, biopsy prognostic Gleason grade groups 1-5 had 4-year biochemical progression-free survival of 95%, 91%, 85%, 78%, and 70%. After adjusting for preoperative serum prostate specific antigen and clinical stage, biopsy prognostic Gleason grade groups were significant independent predictors of biochemical progression after radical prostatectomy and radiotherapy. There was no central review of pathology. Conclusions: These results confirm the prognostic value of the newly proposed prognostic Gleason grade groups in men undergoing radical prostatectomy and radiotherapy in a population-based setting.
APA, Harvard, Vancouver, ISO, and other styles
2

Puyo, Stéphane. "Recherche d’alternatives thérapeutiques aux taxanes dans les cancers de la prostate de hauts grades : identification d’une signature prédictive de la réponse à l’oxaliplatine." Thesis, Bordeaux 2, 2011. http://www.theses.fr/2011BOR21842/document.

Full text
Abstract:
Les cancers de la prostate sont classés en deux catégories. Les cancers de haut grade se distinguent des cancers de bas grade par une plus forte agressivité et un pronostic plus mauvais. Lorsqu’ils deviennent résistants à l’hormonothérapie, les cancers de haut grade sont traités par une chimiothérapie basée sur les taxanes. Néanmoins, les taux de réponse restent faibles. Il existe donc un réel besoin quant à l'identification d'alternatives thérapeutiques qui soient spécifiques de ce type de tumeur. Dans cette optique, notre travail a été de proposer une telle alternative par une approche qui prenne en compte la génétique spécifique des cancers de haut grade. Nous avons exploité une signature de 86 gènes dont le niveau d’expression permet de discriminer entre les tumeurs de haut et de bas grade. Par une approche in silico originale utilisant la banque de données du NCI, nous avons identifié 382 corrélations entre le niveau d’expression de 50 gènes et la sensibilité à 139 agents antiprolifératifs. Parmi ces corrélations, nous avons identifié une signature de 9 gènes qui est spécifique de la réponse à l’oxaliplatine. Cette signature a été confirmée sur le plan fonctionnel dans les lignées cancéreuses prostatiques DU145 et LNCaP. Nous avons donc fourni la preuve de concept que notre approche permet d’identifier de nouvelles molécules pouvant être utilisées en alternative aux taxanes pour traiter spécifiquement les cancers de haut grade. Cette stratégie permet aussi d’identifier de nouveaux marqueurs (gènes) régulant la sensibilité à certains médicaments. Nos résultats démontrent par exemple le rôle des gènes SHMT, impliqués dans la régulation du métabolisme monocarboné, dans la sensibilité spécifique à l’oxaliplatine par un mécanisme qui fait intervenir, du moins en partie, une dérégulation du niveau de méthylation global de l’ADN
Prostate cancers are classified in two categories. High grade cancers are distinguished from low grade cancers by their higher agressivity and worse prognostic. When they become refractory to hormone therapy, high grade cancers are treated with a taxane-based chemotherapy. However, response rates remain low. Therefore, there is a real need for the discovery of new therapeutic alternatives which are specific for this type of tumors. For that purpose, our work aimed at proposing such an alternative with a strategy that took into account the high grade genetic background. We exploited a signature of 86 genes for which expression level could distinguish between low grade and high grade tumours. With an original in silico approach, we searched the NCI databases and identified 382 correlations between 50 genes and the sensitivity to 139 antiproliferative agents. Among these, a signature of 9 genes was able to specifically predict cell response to oxaliplatin. This signature was validated at the functional level in two prostate cancer cell lines, DU145 and LNCaP. We have thus provided the proof-of-concept that our approach allows the identification of new drugs that can be used alternatively to taxanes in order to specifically treat high grade prostate cancers. This strategy also allows the identification of new markers (genes) regulating the sensitivity to various drugs. Our results demonstrate for example the implication of SHMT genes, which are involved in the regulation of the one-carbon metabolism, in the specific sensitivity to oxaliplatin, by a mechanism which involves, at least in part, the deregulation of the global level of DNA methylation
APA, Harvard, Vancouver, ISO, and other styles
3

Hannah, Amir [Verfasser], and Markus [Akademischer Betreuer] Graefen. "Prävalenz und Einfluss eines tertiären Gleason Grades im radikalen Prostatektomiepräparat auf ungünstige histopathologische Parameter und das biochemisch rezidivfreie Überleben nach radikaler Prostatektomie / Amir Hannah. Betreuer: Markus Graefen." Hamburg : Staats- und Universitätsbibliothek Hamburg, 2013. http://d-nb.info/1045024392/34.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Bui, Loan Thuy. "Localisation of kallikreins in the prostate and association with prostate cancer progression." Queensland University of Technology, 2006. http://eprints.qut.edu.au/16276/.

Full text
Abstract:
At present, prostate cancer is a significant public health issue throughout the world and is the second leading cause of cancer deaths in older men. The prostate specific antigen or PSA (which is encoded by the kallikrein 3/KLK3 gene) test is the current most valuable tool for the diagnosis and management of prostate cancer. However, it is insufficiently sensitive and specific for early diagnosis, for staging of prostate cancer or for discriminating between benign prostatic hyperplasia (BPH) and prostate cancer. Recent research has revealed another potential tumour marker, glandular kallikrein 2 (KLK2 gene/hK2 protein), which may be used alone or in conjunction with PSA to overcome some of the limitations of the PSA test. Twelve new kallikrein gene family members have been recently identified and, like hK2 and PSA, many of these genes have been suggested to be involved in carcinogenesis. In this study, the cellular localisation and level of expression of several of these newer kallikreins (KLK4, KLK5, KLK7, KLK8 and KLK11) was examined in prostate tissue, to provide an understanding of the association of their expression with prostatic diseases and their potential as additional biomarkers. Like PSA and hK2, the present observation indicated that each of these proteins, hK4, hK5, hK7, hK8 and hK11, was detected within the cytoplasm of the secretory cells of the prostate glands. For the first time, all of these newly-identified proteins were shown to be expressed in prostatic intraepithelial neoplasia (PIN) lesions, in comparison to normal glands and cancer lesions. In addition to cytoplasmic secretory cell expression, the localisation of hK4 to the basal cells and nuclei in prostatic lesions was intriguing. The intensity of hK4 staining in prostate tissue was strongest in comparison to the other newly-identified kallikrein proteins (hK5, hK7, hK8 and hK11). Therefore, KLK4/hK4 expression was characterised further to define this cellular localisation and examined in non-prostatic tissue and also in a larger number of prostate tissues in an attempt to determine its potential value as a biomarker for prostate disease. Three hK4 antipeptide polyclonal antibodies, derived against N-terminal, mid-region and C-terminal hK4 amino acid sequences, were used. The hK4 N-terminal antipeptide antibody was used to demonstrate the cellular localisation of hK4 in kidney, salivary glands, liver, testis, colon carcinoma, heart, endometrium and ovarian cancer, for the first time. The presence of hK4 in these non-prostate tissues was consistent with the previous reports using RT-PCR. The dual cytoplasmic and nuclear localisation of hK4 observed in the prostate above was also seen in these tissues. Although hK4 was found widely expressed in many human tissue types, indicating that it is not prostate specific in its expression, the highest expression level of hK4 was seen in the prostate. Therefore, detailed expression patterns and levels of KLK4 mRNA and hK4 protein in the normal prostate and prostatic diseases and histopathological lesions were investigated and reported for the first time in this study. Twelve benign prostatic hyperplasia (BPH), 19 adenocarcinoma (Gleason grade 2-5) and 34 bone metastases from prostate cancer were analysed. Using in situ hybridisation, the expression of KLK4 mRNA was detected in the cytoplasm of the secretory cells of both normal and diseased prostate tissue. KLK4 mRNA was also noted in both secretory and basal cells of PIN lesions, but the basal cells of normal glands were negative. Using the hK4 N-terminal and mid-region antipeptide antibodies, hK4 was predominantly localised in the cytoplasm of the secretory cells. The intensity of hK4 staining appeared lowest in normal and BPH, and increased in PIN lesions, high Gleason grade prostate cancer and bone metastases indicating the potential of hK4 as a histopathological marker for prostatic neoplasias. Further studies are required with a larger cohort to determine its utility as a clinical biomarker. Small foci of atypical cells, which were found within normal glands, were also intensely stained. Surprisingly, hK4 protein was found in the nucleus of the secretory cells (but not the basal cells) of high grade PIN and Gleason grade 3 prostate cancer. The detection of KLK4 mRNA and hK4 protein in PIN lesions and small foci of atypical cells suggests that up-regulation of KLK4 expression occurs early in the pathology of prostate carcinogenesis. The finding of basal cell expression is not typical for the kallikreins and it is not clear what role hK4 would play in this cell type. With the use of the hK4 C-terminal antipeptide antibody, the staining was mainly localised in the nuclei of the secretory cells of the prostate glands. Although the nuclear localisation was readily noted in more than 90% of epithelial cells of the prostate gland with the C-terminal antibody, no difference in staining intensity was observed among the histopathological lesions of the prostate. The prominent nuclear localisation with the C-terminal antipeptide antibody was also shown to be distributed throughout the nucleus by using confocal microscopy. Further, by using gold-labelled particles for electron microscopy, the intracellular localisation of these hK4 antipeptide antibodies was reported here for the first time. Similar to the immunohistochemical results, the cytoplasm was the major site of localisation with the N-terminal and mid-region antipeptide antibodies. To further characterise the involvement of KLK4/hK4 in human prostate cancer progression, the transgenic adenocarcinoma mouse prostate (TRAMP) model was used in this study. In this study, mouse KLK4 (also known as enamel matrix serine protease -1, EMSP-1) was shown to be expressed in the TRAMP prostate for the first time. Previous studies had only shown the developing tooth as a site of expression for EMSP-1. The level of EMSP-1 mRNA expression was increased in PIN and prostate cancer lesions of the TRAMP model, while negative or low levels of EMSP-1 mRNA were seen in normal glands or in control mouse prostate tissue. The normal mouse prostate did not stain with any the three hK4 antipeptide antibodies. hK4 N-terminal and mid-region antipeptide antibodies showed positive staining in the cytoplasm of the epithelial cells of PIN and cancer lesions of the mouse prostate. The C-terminal antipeptide antibody showed distinctively nuclear staining and was predominantly localised in the nuclei of the glandular cells of PIN and cancer lesions of the mouse prostate. The expression patterns of both the mRNA and protein level for mouse KLK4 strongly supported the observations of KLK4/hK4 expression in the human prostate and further support the utility of the TRAMP model. Overall, the findings in this thesis indicate a clear association of KLK4/hK4 expression with prostate cancer progression. In addition, several intriguing findings were made in terms of cellular localisation (basal as well as secretory cells; nuclear and cytoplasmic) and high expression in atypical glandular cells and PIN, perhaps indicating an early involvement in prostate disease progression and, additionally, utility as basal cell and PIN histological markers. These findings provide the basis for future studies to confirm the utility of hK4 as a biomarker for prostate cancer progression and identify functional roles in the different cellular compartments.
APA, Harvard, Vancouver, ISO, and other styles
5

Chaniotakis, Sotiris. "Digital image analysis for tumor cellularity and gleason grade to tumor volume analysis in prostate cancer." Thesis, 2018. https://hdl.handle.net/2144/31173.

Full text
Abstract:
PURPOSE: This study was undertaken to compare HALO™ software image analysis measurements of cellularity with visual estimations from the pathologist and to outline a protocol for future experimental determinations of cellularity using HALO™. Secondly, this study investigated the clinically challenging prostate cancers of Gleason score 7 by analyzing a large database of radical prostatectomy (RP) specimens with regard to their Gleason grade composition and percentage tumor volume composition. The importance of these values of tumor cellularity, prostate volume, and tumor volume data were discussed in terms of future diagnostic endeavors. Finally, this study provided a brief background on prostate cancer, prostate cancer epidemiology, digital pathology, and the limitations and difficulties in the technological transition to digital pathology. All work for this study was done at Dana-Farber Cancer Institute (Boston, MA). METHODS: In the first part of this study, histological slides were acquired by radical prostatectomy (RP) and contained 12 tumor foci of varying degrees and sizes. These slides were scanned and imported into the HALO™ image analysis software. The tumor foci, previously demarcated by a pathologist, were annotated by hand in HALO™. An algorithm for image analysis was created by training classifiers to recognize and differentiate between epithelial tissue, stromal tissue, glass, and other. This process was accomplished by classifying 62 regions which were tested for accuracy before becoming the components of an algorithm to analyze the entire annotation layer. Each tumor focus was analyzed individually, and the results were exported into Microsoft® Excel from which relevant data were extracted. Cellularity was calculated by the percentage of tumor area that the algorithm characterized as epithelial. Cellularity values derived from HALO™ measurements for each tumor focus were compared with the visual estimations of cellularity provided by the pathologist using Pearson's correlation analysis. In the second part of this study, a database of 1386 slides containing tumors with Gleason scores between 6 and 9 was compiled from 140 RP cases. The average percentages of Gleason grades 3, 4, and 5 in each case were determined. The percentage of each slide that was occupied by the tumor was also averaged for each case, yielding an average percentage of tumor volume for each case. The average Gleason grade 3, 4, or 5 percentage for each case was plotted against the associated average tumor volume percentage of that case. The cases of Gleason score 7 (3+4, 4+3) were then isolated and plotted in a similar manner. Pearson’s correlation analysis was used to determine the degree of linear correlation between the two variables in each plot. Results: In the first part of this study, a statistically significant positive correlation between the cellularity estimations of the pathologist and the HALO™ cellularity measurements was found (r = 0.92, p < 0.01, n =12). In the second part of this study, there was a statistically significant negative correlation between average Gleason grade 3 percentage per case and average tumor volume percentage per case (r = -0.55, p <0.001, n = 140). There was also a statistically significant positive correlation between average Gleason grade 4 percentage per case and average tumor volume percentage per case (r = 0.55, p <0.001, n = 140). After slides containing Gleason score 6 (3+3) tumor were removed from the data, a statistically significant negative correlation remained between average Gleason grade 3 percentage per case and average tumor volume percentage per case (r = -0.51, p <0.001, n = 78), and a statistically significant positive correlation remained between average Gleason grade 4 percentage per case and average tumor volume percentage per case (r = 0.5, p <0.001, n = 101). A statistically significant relationship between average Gleason grade 5 percentage and average tumor volume percentage was not found (r = 0.32, p = 0.14, n = 23). CONCLUSIONS: In the first part of this study, the strong positive correlation between HALO™ cellularity values and visual estimations by the pathologist suggests that image analysis may be an effective tool for determining cellularity in digital histological images. More research using larger sample sizes is recommended to further validate the correlation between algorithm-derived cellularity from HALO™ and visual estimation by the pathologist. In the second part of this study, it appears that the volume of prostate tumors of Gleason score 7 may have prognostic power, considering that an increased percentage composition of Gleason grade 4 correlated with larger tumor volumes. Because this result may have significant clinical implications, further research specifically on tumors of Gleason score 7 is suggested to verify this relationship.
APA, Harvard, Vancouver, ISO, and other styles
6

Ghleilib, Intisar Ali. "The accuracy of prostate biopsy to assign patients with low-grade prostate cancer to active surveillance." Thesis, 2014. https://hdl.handle.net/2144/15352.

Full text
Abstract:
PURPOSE: To determine the accuracy of prostate biopsy Gleason score (GS) compared to prostatectomy GS. To determine whether a biopsy is a satisfactory diagnostic procedure to offer active surveillance for patients with low-grade prostate cancer. METHODS: This study was conducted in Tuft Medical Center as retrospective cohort study over the period from 2007-2010. The study included 83 patients for whom biopsy and prostatectomy GS were available. MEASUREMENTS: Gleason scores of 6, 7, and 8-10 were assigned to low, moderate, and high-grades, respectively. The kappa statistic was calculated to assess the degree of agreement between biopsy and prostatectomy. The ROC curve was used to evaluate the sensitivity and specificity of prostate biopsy for different Gleason grades. Also, compared whether the use of specific criteria for active surveillance (Johns Hopkins and UCSF) may decrease the level of up-grading in patient with low-grade prostate cancer using Chi-square test. RESULTS: The distribution of low, moderate, and high-grade cancer in biopsy (52%, 32%, 16%) and prostatectomy specimen (33%, 55%, 12%) showed fair agreement with weighted kappa 0.35. The prostate biopsy accurately predicted GS in 46%, up-graded in 38%, and down-graded in 16%. The patients with low-grade cancer and potentially eligible for active surveillance showed up-grading in 50% of cases. This up-grading reduced to 40% with the use of Johns Hopkins criteria and to 41% with the use of UCSF criteria. CONCLUSIONS: The accuracy of biopsy GS in predicting prostatectomy GS is severely limited and therefore biopsy is not enough diagnostic procedure to offer active surveillance.
APA, Harvard, Vancouver, ISO, and other styles
7

Hansen, Jens [Verfasser]. "Klinische Überprüfung präinterventioneller Daten von Patienten mit High-grade-Prostatakarzinom (Gleason ≥ 4+4) zur Optimierung des Therapieergebnisses / vorgelegt von Jens Hansen." 2010. http://d-nb.info/1008097721/34.

Full text
APA, Harvard, Vancouver, ISO, and other styles

Books on the topic "Grade de Gleason"

1

Bjartell, Anders, and David Ulmert. Clinical features, assessment, and imaging of prostate cancer. Edited by James W. F. Catto. Oxford University Press, 2017. http://dx.doi.org/10.1093/med/9780199659579.003.0063.

Full text
Abstract:
In contemporary practice, most patients with prostate cancer are diagnosed following a prostate-specific antigen (PSA) test and are asymptomatic at the time of diagnosis. Although serum PSA has a low specificity for prostate cancer, it can be used to single out patients with advanced disease. While most men do not have a palpable tumour at digital rectal examination (DRE), those with palpable or an elevated PSA test require transrectal ultrasonography-guided prostate biopsy in order to make a diagnosis of cancer. Tumours are staged clinically as localized, locally advanced, or metastatic. The urologist and the patient need the correct staging information for decision-making. A combination of several parameters (PSA value, Gleason grade and tumour extent on biopsy, and DRE findings) can be used in a variety of tools to predict the extent of the disease and treatment outcomes.
APA, Harvard, Vancouver, ISO, and other styles
2

Cooperberg, Matthew, and Peter Carroll. Prostate cancer. Edited by James W. F. Catto. Oxford University Press, 2017. http://dx.doi.org/10.1093/med/9780199659579.003.0064.

Full text
Abstract:
Management of prostate cancer remains controversial, in large part because of its wide heterogeneity in terms of aggressiveness and prognosis. Early detection efforts based on prostate specific antigen (PSA) and aggressive treatment of high-risk cancers have yielded major improvements in mortality rates, but overtreatment of low-risk cancers—those unlikely to cause symptoms or threaten life if they were never detected—is associated with high rates of avoidable toxicity and cost. Prostate cancer can be effectively risk-stratified based on tools (e.g. nomograms, CAPRA score) integrating the PSA level, Gleason grade, clinical stage, and extent of biopsy tissue involvement. Most men with low-risk tumours are eligible for active surveillance, a programme of careful monitoring based on PSA and follow-up biopsies. Men with higher-risk cancers are best served with radical prostatectomy or radiation therapy.
APA, Harvard, Vancouver, ISO, and other styles
3

The Blue Wall, a Grace Gleason Files Series Novel. Sunstone Press, 2014.

Find full text
APA, Harvard, Vancouver, ISO, and other styles

Book chapters on the topic "Grade de Gleason"

1

Mahapatra, Dwarikanath, Shiba Kuanar, Behzad Bozorgtabar, and Zongyuan Ge. "Self-supervised Learning of Inter-label Geometric Relationships for Gleason Grade Segmentation." In Domain Adaptation and Representation Transfer, and Affordable Healthcare and AI for Resource Diverse Global Health, 57–67. Cham: Springer International Publishing, 2021. http://dx.doi.org/10.1007/978-3-030-87722-4_6.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Casey, Matthew, and Nianjun Zhou. "Analysis of Viability of TCGA and GTEx Gene Expression for Gleason Grade Identification." In Artificial Intelligence in Medicine, 475–85. Cham: Springer International Publishing, 2020. http://dx.doi.org/10.1007/978-3-030-59137-3_42.

Full text
APA, Harvard, Vancouver, ISO, and other styles

Conference papers on the topic "Grade de Gleason"

1

Almuntashri, Ali, Sos Agaian, Ian Thompson, Danny Rabah, Osman Zin Al-Abdin, and Marlo Nicolas. "Gleason grade-based automatic classification of prostate cancer pathological images." In 2011 IEEE International Conference on Systems, Man and Cybernetics - SMC. IEEE, 2011. http://dx.doi.org/10.1109/icsmc.2011.6084080.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Arvidsson, Ida, Niels Christian Overgaard, Agnieszka Krzyzanowska, Felicia-Elena Marginean, Athanasios Simoulis, Anders Bjartell, Kalle Åström, and Anders Heyden. "Domain-adversarial neural network for improved generalization performance of Gleason grade classification." In Digital Pathology, edited by John E. Tomaszewski and Aaron D. Ward. SPIE, 2020. http://dx.doi.org/10.1117/12.2549011.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Esser, Alison K., Christine J. Weydert, Melissa M. Meier, Daniel Beltran-Valero de Bernabe, Brian J. Smith, Michael B. Cohen, Kevin P. Campbell, and Michael D. Henry. "Abstract 421: Dystroglycan glycosylation status predicts Gleason grade and influences prostate tumor growth." In Proceedings: AACR 101st Annual Meeting 2010‐‐ Apr 17‐21, 2010; Washington, DC. American Association for Cancer Research, 2010. http://dx.doi.org/10.1158/1538-7445.am10-421.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Tall, Kasper, Ida Arvidsson, Niels Christian Overgaard, Kalle Åström, and Anders Heyden. "Automatic detection of small areas of Gleason grade 5 in prostate tissue using CNN." In Digital Pathology, edited by John E. Tomaszewski and Aaron D. Ward. SPIE, 2019. http://dx.doi.org/10.1117/12.2512924.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Yoshimoto, Maisa, Andrew Evans, Joan Sweet, Olga Ludkovski, Keyue Ding, Greg Trottier, Kyu S. Song, and Jeremy A. Squire. "Abstract 320: Association of higher Gleason grade with presence of PTEN deletion in prostatic adenocarcinoma." In Proceedings: AACR 102nd Annual Meeting 2011‐‐ Apr 2‐6, 2011; Orlando, FL. American Association for Cancer Research, 2011. http://dx.doi.org/10.1158/1538-7445.am2011-320.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Jiménez del Toro, Oscar, Manfredo Atzori, Sebastian Otálora, Mats Andersson, Kristian Eurén, Martin Hedlund, Peter Rönnquist, and Henning Müller. "Convolutional neural networks for an automatic classification of prostate tissue slides with high-grade Gleason score." In SPIE Medical Imaging, edited by Metin N. Gurcan and John E. Tomaszewski. SPIE, 2017. http://dx.doi.org/10.1117/12.2255710.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Veltri, Robert W., Christhunesa Christudass, Jonathan I. Epstein, Sahirzeeshan Ali, Hong-Jun Yoon, Ching-Chung Li, and Anant Madabhushi. "Abstract 4061: Computer-assisted Gleason grading of prostate cancer: Two novel approaches using nuclear shape and texture feature to classify pathologic Gleason grade patterns 3 and 4." In Proceedings: AACR 103rd Annual Meeting 2012‐‐ Mar 31‐Apr 4, 2012; Chicago, IL. American Association for Cancer Research, 2012. http://dx.doi.org/10.1158/1538-7445.am2012-4061.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Zong, Weiwei, Eric Carver, Aharon Feldman, Joon Lee, Zhen Sun, Lanyu Xu, Ali Dabaja, and Ning Wen. "Abstract 186: Gleason grade group predictions from mp-MRI of prostate cancer patients using auto deep learning." In Proceedings: AACR Annual Meeting 2021; April 10-15, 2021 and May 17-21, 2021; Philadelphia, PA. American Association for Cancer Research, 2021. http://dx.doi.org/10.1158/1538-7445.am2021-186.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Donovan, Michael Joseph, Gerardo Fernandez, Richard Scott, Jack Zeineh, Giovanni Koll, Faisal Khan, Nataliya Gladoun, Elizabeth Charytonowicz, Ash Tewari, and Carlos Cordon-Cardo. "Abstract B093: Development and validation of a novel automated Gleason grade and molecular profile that define a highly predictive prostate cancer progression algorithm-based test." In Abstracts: AACR Special Conference: Prostate Cancer: Advances in Basic, Translational, and Clinical Research; December 2-5, 2017; Orlando, Florida. American Association for Cancer Research, 2018. http://dx.doi.org/10.1158/1538-7445.prca2017-b093.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Sridharan, Shamira, Virgilia Macias, Krishnarao Tangella, Andre Kajdacsy-Balla, and Gabriel Popescu. "QPI for prostate cancer diagnosis: quantitative separation of Gleason grades 3 and 4." In SPIE BiOS, edited by Gabriel Popescu and YongKeun Park. SPIE, 2015. http://dx.doi.org/10.1117/12.2080067.

Full text
APA, Harvard, Vancouver, ISO, and other styles

Reports on the topic "Grade de Gleason"

1

Nelson, Peter S. Exploiting a Molecular Gleason Grade for Prostate Cancer Therapy. Fort Belvoir, VA: Defense Technical Information Center, March 2008. http://dx.doi.org/10.21236/ada493175.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Nelson, Peter S. Exploiting a Molecular Gleason Grade for Prostate Cancer Therapy. Fort Belvoir, VA: Defense Technical Information Center, March 2009. http://dx.doi.org/10.21236/ada504023.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Nelson, Peter S. Exploiting a Molecular Gleason Grade for Prostate Cancer Therapy. Fort Belvoir, VA: Defense Technical Information Center, March 2010. http://dx.doi.org/10.21236/ada526580.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Eckhert, Curtis D. Microlocalization and Quantitation of Risk Associated Elements in Gleason Graded Prostate Tissue. Fort Belvoir, VA: Defense Technical Information Center, March 2005. http://dx.doi.org/10.21236/ada437695.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Eckhert, Curtis D. Microlocalization and Quantitation of Risk Associated Elements in Gleason Graded Prostate Tissue. Fort Belvoir, VA: Defense Technical Information Center, March 2006. http://dx.doi.org/10.21236/ada463233.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Eckhert, Curtis D. Microlocalization and Quantitation of Risk Associated Elements in Gleason Graded Prostate Tissue. Fort Belvoir, VA: Defense Technical Information Center, March 2007. http://dx.doi.org/10.21236/ada478413.

Full text
APA, Harvard, Vancouver, ISO, and other styles
You might also be interested in the extended bibliographies on the topic 'Grade de Gleason' for particular source types:
Journal articles
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

To the bibliography